Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | SELE | P16581 | 5/20 | 0.61 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372449 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13195877 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29405702 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13978771 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29448496 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29391699 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29407985 | 0.99 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466129 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466139 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL31010809 | 0.96 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | claimed |
| US-20250223649-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | MERCY BIOANALYTICS, INC. | 2025-07-10 | — | — | US | claimed |
| EP-4460697-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | Mercy Bioanalytics, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2024191702-A2 | P-SELECTIN INHIBITION TO TREAT HUMAN LYMPHEDEMA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-09-19 | — | — | WO | claimed |
| CN-118510547-A | Targeted linear conjugates comprising polyethylenimine and polyethylene glycol and polymer complexes comprising the same | 塔尔格免疫治疗有限公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2023133299-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023113596-A1 | DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-06-22 | — | — | WO | claimed |
| US-11639389-B2 | Binding molecules with modified J-chain | IGM BIOSCIENCES, INC. (US) | 2023-05-02 | — | — | US | claimed |
| EP-3568162-B1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12486336-B2 | Binding molecules with modified J-chain | IGM BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | disclosed |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250223649-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | MERCY BIOANALYTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2022178510-A1 | NANOPARTICLES FOR USE IN TREATING VIRAL INFECTIONS | HILLSTREAM BIOPHARMA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11419943-B2 | Polymer-sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2022-08-23 | — | — | US | disclosed |
| US-11406618-B2 | Polymer-des-ethyl sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220175874-A1 | POLYMERIC NANOPARTICLES AND A PROCESS OF PREPARATION THEREOF | GRAVITAS LIFE SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175688-A1 | POLYMERIC NANOPARTICLES | HILLSTREAM BIOPHARMA INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-11246904-B2 | Polymeric nanoparticles and a process of preparation thereof | HILLSTREAM BIOPHARMA, INC. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | FCGR2A, FCGR3B, FCGR1A | SELP 206/4885SELL 965/4885SIGLEC7 12/4885 |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | SELP 206/4885SELL 965/4885SIGLEC7 12/4885 |
| US-11406618-B2 | Polymer-des-ethyl sunitinib conjugates | KDR, FLT4, FLT1 | SELP 62/4885SELL 76/4885SIGLEC7 1853/4885 |
| US-11419943-B2 | Polymer-sunitinib conjugates | FLT4, TEK, TIE1 | SELP 83/4885SELL 55/4885SIGLEC7 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.